Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

In collaboration with partner HHP, University of Chicago Medicine's food hall at the Center for Care and Discovery (CCD) is celebrating its grand opening this ...

Foremost experts in Movement Disorders, which include the fastest-growing brain disease, will convene to share about and guide the direction of global advancements like artificial intelligence.

Glucagon-like peptide-1 receptor (GLP-1) agonist medications have become increasingly popular thanks to their effectiveness for weight loss and blood sugar management. To get these medications ...

Why Trust Us? GLP-1 receptor agonists like Ozempic and Wegovy have a lot of scientific data to support their use—and they can help people drop a lot of pounds. But is it possible to get the same ...

Weight loss with Ozempic or Wegovy can be effective, but expensive. Enter so-called GLP-1 supplements that have taken on the nickname “nature’s Ozempic.” They’re much cheaper than the ...

The latest supplement on the scene? Lemme GLP-1 Daily, a supplement that purports to boost GLP-1 levels, reduce hunger cravings, promote fat reduction, and support weight management. Lemme ...